The Raf-mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)-AKT pathways are two downstream effectors of the small GTPase Ras. Although both pathways are positively regulated by Ras, the Raf-MAPK and PI3K-AKT pathways have been shown to control opposing functions within the cell, suggesting a need for cross-talk regulation. The PI3K-AKT pathway can inhibit the Raf-MAPK pathway directly during processes such as muscle differentiation. Here we describe the ability of the Raf-MAPK pathway to negatively regulate the PI3K-AKT pathway during cellular arrest. Constitutive activation of Raf or methyl ethyl ketone 1 (MEK1) leads to inhibition of AKT and cellular arrest. Furthermore, we show that activation of Raf-MEK1 signaling causes negative feedback inhibition of Ras through the ephrin receptor EphA 2 . EphA 2 -mediated negative feedback inhibition is required for Raf-induced AKT inhibition and cell cycle arrest, therefore establishing the inhibition of the Ras-PI3K-AKT pathway as a necessary event for the Raf-MEK1-regulated cellular arrest.
Introduction
Growth factor-mediated activation of Ras, and subsequently the Raf-mitogen-activated protein kinase (MAPK) pathway, provides a positive signal for proliferation in various cell types and tissues (reviewed in Chong et al., 2003) . Constitutive activation mutants of either Ras or Raf, in contrast, can elicit a potent p21CIP-mediated cellular arrest in both primary human and murine cells (Serrano et al., 1997; Sewing et al., 1997; Woods et al., 1997) . In fact, the intensity and duration of the signal through the Ras-Raf-MAPK pathway ultimately determines the physiological output within the cell (Sewing et al., 1997) . Another important downstream effector of the small GTPase Ras is the phosphatidylinositide 3-kinase (PI3K)-AKT signaling pathway (reviewed in Lawlor and Alessi, 2001; Scheid and Woodgett, 2001; Luo et al., 2003) . AKT itself phosphorylates a myriad of substrates within the cell to regulate survival, cellular proliferation, differentiation and insulin responsiveness (Brazil et al., 2002) .
While the PI3K-AKT and Raf-MAPK pathways are both found to be hyperactive in cancer, they also can control opposing activities within normal cellular processes. The PI3K-AKT pathway can be activated independent of Ras and, depending on the strength and duration of that signal, may antagonize processes regulated by the Raf-MAPK pathway. Therefore, there needs to be cross talk between these pathways so that opposing signals can be resolved.
Cross-talk regulation between the Raf-MAPK and AKT pathways was first observed during muscle cell differentiation (Rommel et al., 1999; Zimmermann and Moelling, 1999) . During muscle cell hypertrophy, Raf-MEK-ERK and PI3K-AKT activities exert opposing effects (Rommel et al., 1999) . PI3K-AKT activation promotes differentiation, while the Ras-Raf-MAPK pathway inhibits myogenic conversion of precursor cells (Rommel et al., 1999) . Interestingly, AKT was shown to phosphorylate Raf directly at serine 259 to inhibit MAPK activity during muscle cell differentiation (Rommel et al., 1999; Zimmermann and Moelling, 1999) . This cross-talk inhibition of the Raf-MAPK pathway by PI3K-AKT was required for the differentiation of muscle cells and provides the first cellular process exhibiting cross-talk signaling between these two pathways. PI3K-AKT inhibition of Raf-MAPK signaling is also required for vascular smooth muscle and intestinal epithelial cell differentiation (Reusch et al., 2001 ; Laprise et al., 2004) .
Although cross-talk regulation was established where PI3K-AKT activation can inhibit Raf-MAPK signaling, converse Raf-MAPK cross-talk regulation of PI3K-AKT was not initially observed in cells. Previous work in our laboratory provided the first evidence of such signaling cross talk in the context of cellular arrest (Westbrook et al., 2002) . We demonstrated that constitutive activation of the Raf-MAPK pathway led to specific inhibition of AKT and that this cross talk was required for the arrest (Westbrook et al., 2002) . It was not clear how constitutive activation of the Raf-MAPK pathway caused inhibition of AKT activity and what downstream events of Raf activation were required for this cross talk.
In this study, we provide evidence that activation of Raf causes inhibition of AKT and cellular arrest specifically through MEK1. Furthermore, we show that constitutive Raf-MEK1 signaling leads to negative feedback inhibition of the upstream regulator Ras through the ephrin receptor EphA 2 , and this event is required for cellular arrest. Together, these data identify the EphA 2 -mediated negative feedback inhibition of the Ras-PI3K-AKT pathway as an important and required step in Raf-induced cell cycle arrest.
Results
Constitutive Raf-MAPK signaling leads to inhibition of AKT activity Previous work in our laboratory established signaling cross talk between the Raf-MAPK and PI3K-AKT pathways in 3T3 fibroblasts (C4 cells) expressing a conditional Raf-AR molecule (Westbrook et al., 2002) . High-intensity Raf signaling led to a specific inhibition of AKT activity and this inhibition was required for the cell cycle arrest elicited by Raf activation (Westbrook et al., 2002) . The conditional Raf molecule can be activated to various signaling intensities by using varying amounts of the androgen analog R1881, added to the media of the cells (Sewing et al., 1997) . To further establish the direct inhibition of AKT activity by Raf signaling, various degrees of Raf activation were achieved by titrating the amount of R1881 added to the media of the C4 cells. AKT activity was monitored by western blot with a phospho-AKT (serine 473) antibody ( Figure 1a) . Consistent with our previous study, activation of Raf-MAPK signaling led to inhibition of AKT in a titratable manner (Figure 1a ). Phospho-ERK1/2, a downstream effector of Raf, was also monitored by western blot to observe Raf-MAPK activity. Phospho-ERK1/2 levels increased conversely to the levels of phosphorylated AKT (Figure 1a) . Total ERK and AKT are shown as loading controls for the experiment. As an alternative method of arresting the cells, we used a constitutively active Raf molecule, which also reduced the level of active AKT (Figure 1b) .
Activation of Raf with the highest concentration of R1881 (Figure 1a) led to a specific cell cycle arrest in the fibroblasts after 32 h, as assessed by 5-bromodeoxyuridine (BrdU) incorporation (Figure 1c ). Previous reports have established that activation of AKT in the presence of Raf signaling prevents Raf-mediated cell cycle arrest (Westbrook et al., 2002; Mirza et al., 2004) . We have also shown that loss of AKT activity during Raf activation arrest is required for p21-mediated cell cycle arrest (Westbrook et al., 2002) . Together, these data show the importance of AKT activity in regulating cellular responses to constitutive Raf-MAPK signaling.
Raf requires MEK1 and protein synthesis for inhibition of AKT activity Although we have established that constitutive activation of the Raf-MAPK leads to inhibition of AKT, the mechanism by which this cross talk occurs is unknown. To dissect how Raf-MAPK signaling alters AKT activity, we wanted to investigate what was required of the Raf-MAPK pathway to elicit this effect on AKT. One plausible mechanism would involve a negative regulator of AKT activity being upregulated by MAPK signaling. To address this possibility, the high-intensity Raf signal was turned on in the presence or absence of cyclohexamide, an inhibitor of de novo protein synthesis, for 8 h and cells were harvested. AKT activity was again monitored by western blot with the phospho-AKT (serine 473) antibody. In the presence of cyclohexamide, Raf was unable to inhibit AKT phosphorylation when RafAR NIH-3T3 fibroblasts (C4 cells) were plated at subconfluence and Raf was activated with varying concentrations of the androgen analog R1881 (0, 5, 25, 100, 500 and 1000 nM). Cells were harvested after 8 h and western blot analysis was performed to evaluate P-AKT (serine 473), total AKT, P-ERK and ERK2 levels. (b) C4 cells were treated or not with 500 nM R1881 for 32 h before being pulsed and stained for 5-bromodeoxyuridine incorporation.
Raf-MEK1 regulates Ras-PI3K-AKT through EphA 2 CW Menges and DJ McCance compared to controls ( Figure 2a , set 2), suggesting that Raf-MAPK signaling requires protein synthesis for inhibition of AKT.
We also wanted to establish whether MEK activity, the kinase directly downstream of Raf, was required for inhibition of AKT. Since Raf can signal independently of the MAPK pathway, we wanted to determine which downstream effectors, MEK-dependent or -independent, are required for AKT inhibition. The MEK inhibitor U0126, with or without R1881, was added to the media and cells were harvested 8 h later. Addition of U0126 blocked the ability of Raf to inhibit AKT phosphorylation ( Figure 2a , set 3), suggesting that Raf signals through the MAPK cascade to have its effect on AKT. The same result was observed when MEK activity was inhibited with another MEK inhibitor PD98059 (data not shown).
MEK inhibitors provided evidence that Raf may signal through MEK to inhibit AKT phosphorylation. Although chemical MEK inhibitors have been used previously in the literature, kinase inhibitors in general are promiscuous and can often inhibit other kinases nonspecifically, depending on the concentration and duration of treatment. To circumvent this potential problem, we wanted to evaluate whether activating MEK by itself was sufficient to inhibit AKT activity. MEK exists in two isoforms in the cell, MEK1 and MEK2, so constitutively active point mutants of each isoform (CA-MEK1/CA-MEK2) were evaluated in NIH-3T3 cells for their ability to inhibit AKT phosphorylation.
NIH-3T3 cells were stably transfected with increasing amounts of CA-MEK1 or CA-MEK2. Both molecules are hemagglutinin (HA)-tagged, so relative expression within the cell could be evaluated by HA western blot (Figure 2b ). CA-MEK1/2 molecules were expressed to similar levels and activated downstream ERK1/2 in a titratable manner (Figure 2b ). Interestingly though, only CA-MEK1 was able to inhibit AKT phosphorylation, similar to what was observed with Raf activation (Figures 1a and 2b ). CA-MEK2 expression had no effect on AKT phosphorylation, but could activate ERK1/2 to the same extent as CA-MEK1 (Figure 2b ). Total AKT and ERK2 are shown as loading control. Together, these data suggest that activated Raf signals through MEK1, but not MEK2, to inhibit AKT activity. It also suggests that Raf inhibits AKT phosphorylation independent of ERK1/2 activation, since CA-MEK2 also activated ERK but did not inhibit AKT (Figure 2b ), although ERK involvement in these phenomena has not been formally tested.
Raf-MEK1 activation causes inhibition of both Ras and AKT activity
Our previous data suggest that active Raf signals through MEK1 to inhibit AKT activity. While we have established what is required for the cross talk between these two pathways, we have not identified the upstream factor that is lost to inhibit AKT activity. When evaluating putative upstream regulators of the PI3K-AKT pathway, the small GTPase Ras is a potentially interesting Raf-MAPK target, due to the fact that it regulates both Raf-MAPK and PI3K-AKT signaling. If this is the case, we could be observing a negative feedback loop, induced by constitutive Raf signaling, that would lead to inhibition of both Ras and AKT activity.
To evaluate this hypothesis, Raf was activated in C4 cells for 8 h with the various concentrations of R1881 (0, 0.1 and 1 mM). Cells were harvested and lysates were used for GST-Raf-RAS binding domain pulldowns to evaluate Ras activity or western blot to analyze active AKT in the cells. In Figure 3a , activation of Raf with both the concentrations of R1881 led to inhibition of AKT phosphorylation. Interestingly, Ras-GTP levels, or active Ras, decreased to a similar extent as AKT in the presence of Raf signaling (Figure 3a) . These data suggest that constitutive Raf activation leads to parallel inhibition of both Ras and AKT.
Since CA-MEK1 caused inhibition of AKT phosphorylation to the same extent as active Raf, we wanted to determine if it was also sufficient to inhibit Ras activity in cells. NIH-3T3 were stably transfected with increasing amounts of CA-MEK1 and CA-MEK2 and lysates were prepared for Ras activity assays and western blots. CA-MEK1 and CA-MEK2 were expressed at similar levels, as observed by HA western 
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Figure 2 Raf requires de novo protein synthesis and MEK1 activity for inhibition of AKT. (a) Raf was activated in the presence or absence of 10 mM U0126 or 50 mg ml À1 cycloheximide (CXM) for 8 h and western blot analysis was performed to analyse P-AKT (serine 473) and total AKT levels. (b) Increasing amounts of constitutively active (CA) hemagglutinin (HA)-tagged MEK1 and MEK2 were stably transfected into NIH-3T3. Cells were harvested and western blot analysis was performed to monitor HA, P-AKT (serine 473), total AKT, P-ERK and ERK2 levels.
Raf-MEK1 regulates Ras-PI3K-AKT through EphA 2 CW Menges and DJ McCance blot, and both activated the downstream effector ERK1/2 (Figure 3b ). Consistent with previous data, only CA-MEK1 could inhibit AKT phosphorylation in a signal-dependent manner (Figure 3b, left panel) . Interestingly, CA-MEK1 inhibited both Ras and AKT activity to a similar extent (Figure 3b , left panel). CA-MEK2 was unable to inhibit either Ras or AKT activity (Figure 3b, right panel) . Together, these data suggest that Raf inhibits both Ras and AKT through MEK1. Although these data suggest that Akt activity may be lost due to Raf-MEK1 negative feedback inhibition of the upstream regulator Ras, this possibility has not been examined in our system. If loss of Ras activity due to constitutive Raf-MEK1 signaling resulted in loss of AKT activity, then introducing a constitutively active H-Ras molecule (H-RasV12) should prevent Raf-induced AKT inhibition. The conditionally active RafAR C4 cells were infected with retroviruses expressing H-RasV12 or vector alone and selected. The resulting cell lines, pBabe or H-RasV12 C4 cells, were then evaluated for the ability of Raf to inhibit AKT activity. Activation of Raf led to a specific inhibition of AKT activity in control pBabe cells, while Raf activation did not inactivate AKT in the presence of H-RasV12 (Figure 3c ), suggesting that Raf does inhibit AKT through negative feedback regulation of Ras.
It has been previously demonstrated that loss of AKT activity is required for Raf-induced cell cycle arrest (Westbrook et al., 2002) . If this is true, then H-RasV12 expression should also prevent the cell cycle arrest induced by Raf activation, consistent with its ability to prevent AKT inhibition. In Figure 3d , Raf was activated or not in pBabe and H-RasV12 cells and proliferation was evaluated via BrdU incorporation. A twofold decrease in proliferating cells was observed in control pBabe cells in the presence of Raf signaling (Figure 3d) . Interestingly, RasV12 expression partially rescued Raf-induced cell cycle arrest, consistent with its effects on Akt activity. These results point to a mechanism where Raf-induced negative feedback inhibition of Ras causes loss of AKT activity and, consequently, contributes to the cellular arrest.
Raf upregulates EphA 2 receptor to inhibit Ras-PI3K-AKT The previous data established that constitutive Raf-MEK1 signaling led to a potent inhibition of the Ras-PI3K-AKT pathway and this event was required for eliciting cellular arrest. While we have shown that Raf-induced AKT inhibition was a result of negative feedback inhibition of Ras, it is still unclear how constitutive Raf signaling causes loss of Ras activity. Interestingly, treatment with cyclohexamide prevented Raf activation from inhibiting AKT phosphorylation (Figure 2a ), suggesting that a negative regulator of Ras-PI3K-AKT signaling needed to be translated for negative feedback inhibition to occur. Recent data by Macrae et al. (2005) established that constitutive Raf signaling led to the upregulation of the ephrin receptor EphA 2 , causing a negative feedback inhibition of Ras activity. Interestingly, they found that this negative feedback loop was absent in breast cancer cells, underlining its importance in regulating cell growth (Macrae et al., 2005) . The fact that we observe the same negative feedback inhibition of Ras and require protein synthesis for inactivation of AKT made EphA 2 a likely candidate that is induced by Raf to inhibit the Ras-PI3K-AKT pathway.
To evaluate this possibility, Raf was activated in C4 cells with increasing concentrations of R1881 for 12 h and cells were harvested for western blot analysis. In Figure 4a , we can see a titratable increase in EphA 2 protein levels as more R1881 was added to the cells.
Increased EphA 2 receptor levels correlated with inhibition of both Ras and AKT activity. Previous experiments with chemical inhibitors suggested that Raf signaling required de novo protein synthesis and MEK activity to inhibit AKT (Figure 4b ). To address whether protein synthesis and MEK activity were required for EphA 2 upregulation, Raf was activated in the presence or absence of cyclohexamide and U0126 in C4 cells. Both cyclohexamide and U0126 significantly reduced the levels of EphA 2 when compared to control, and Figure 2b , CA-MEK1 and CA-MEK2 were stably transfected into NIH-3T3. Cells were harvested and ras activity pulldowns and western blot analysis were performed to monitor RasGTP, Ras, P-AKT (serine 473), total AKT, P-ERK and ERK2. (c) C4 cells were transduced with pBabe and pBabeRasV12 retroviruses and selected with puromycin. Raf was activated and western blot analysis were performed to monitor P-AKT (serine 473), P-ERK, Ras and total AKT levels. (d) pBabe and pBabe-RasV12 C4 cells were treated or not with 1 mM R1881 for 32 h before being pulsed and stained for 5-bromodeoxyuridine incorporation.
Raf-MEK1 regulates Ras-PI3K-AKT through EphA 2 CW Menges and DJ McCance prevented inhibition of AKT activity (Figure 4b , sets 2 and 3). Conversely, in the absence of either inhibitor, Raf activation led to upregulation of EphA 2 and inactivation of AKT (Figure 4b , set 1). Together, these data demonstrate that EphA 2 is a bona fide target of Raf signaling and its upregulation correlates with loss of Ras and Akt activity. To further establish if Raf-induced upregulation of the EphA 2 receptor is required for loss of AKT activity, short-hairpin RNA (shRNA) targeting EphA 2 (shEphA 2 ) or no known annotated gene (shScram) was transduced and expressed in the conditional C4 cells. Raf was activated in both cell lines and Akt activity was again evaluated by western blot. In control shScram cells, activation of Raf led to a specific increase in EphA 2 levels and loss of active AKT (Figure 4c,left) . In contrast, both EphA 2 levels and AKT activity were unchanged in shEphA 2 cells, suggesting that Raf-induced upregulation EphA 2 is required for inhibition of AKT.
Knocking down EphA 2 prevented Raf-induced inhibition of AKT, a required event for the cellular arrest elicited by constitutive activation of the Raf-MAPK pathway. Thus, we would hypothesize that Rafmediated cell cycle arrest would also be prevented in shEphA 2 knockdown cells. Indeed, knocking down EphA 2 partially prevented cellular arrest in Raf-MAPK activated cells, whereas a twofold decrease in BrdUpositive cells was observed in shScram control cells in the presence of constitutive Raf signaling (Figure 4d ).
Discussion
Negative feedback inhibition of the small GTPase Ras by the ephrin receptor EphA 2 can be lost during cancer progression (Macrae et al., 2005) . Here we identify the PI3K-AKT pathway as another important pathway that is inactivated in normal cells by EphA 2 -mediated negative feedback inhibition of Ras. Furthermore, we show that inhibition of the Ras-PI3K-AKT pathway by EphA 2 is required for Raf-induced cellular arrest.
Our data demonstrate that constitutive activation of the Raf-MAPK signaling axis leads to inhibition of AKT and cell cycle arrest (Figure 1) . Inhibitor studies show a need for MEK activity and protein synthesis for Raf-induced AKT inhibition (Figure 2a) . Interestingly, only constitutive activation of MEK1, not MEK2, was sufficient to elicit inactivation of AKT activity (Figure 2b) , consistent with a model of Raf signaling directly to MEK1 to inhibit AKT activity. Although this would seem counterintuitive at first, there is evidence in the literature that suggests that only MEK1, not MEK2, can substitute for activated Raf in different systems (Hobbs et al., 2004; Scholl et al., 2004) . These two independent groups showed that only activated MEK1, not MEK2, could phenocopy the effects of activated Raf on skin differentiation in mice (Hobbs et al., 2004; Scholl et al., 2004) . There is also evidence in the literature that MEK can signal independently of ERK to have effects in the cell (Holt et al., 1996) . This is consistent with what is observed in this study in that both MEK1/2 upregulated ERK activity, but only MEK1 inhibited Ras-PI3K-AKT, suggesting MEK1 signals independent of ERK to have its effect on Ras and AKT.
Both the Raf-MAPK and PI3K-AKT pathways are regulated by the small GTPase Ras (Warne et al., 1993; Zhang et al., 1993; Rodriguez-Viciana et al., 1994) . Thus negative feedback regulation of Ras by constitutive Raf-MAPK signaling may lead to inhibition of the PI3K-AKT pathway. In line with this hypothesis, we observed specific inhibition of Ras activity by constitutive activation of either Raf or MEK1 (Figures 3a and  b) , consistent with the inactivation of AKT. Furthermore, we could rescue Raf-induced inactivation of AKT and cell cycle arrest by expressing a Ras mutant (RasV12) that cannot be normally regulated ( Figures  3c and d) , further demonstrating a negative feedback loop activated by Raf-MEK1 that inhibited Ras-PI3K-AKT signaling and caused cellular arrest.
The ephrin receptor EphA 2 was recently identified as a transcriptional target of the Raf-MAPK pathway that caused negative feedback inhibition of Ras in normal cells (Macrae et al., 2005) . The fact that we observe the same negative feedback inhibition of Ras-PI3K-AKT and require protein synthesis for this effect made EphA 2 a likely downstream target of Raf-MAPK signaling. Cells were harvested after 8 h and western blot analysis was performed to evaluate EphA 2 (*nonspecific band), P-ERK, ERK2 and actin levels. (b) Raf was activated in the presence or absence of 10 mM U0126 or 50 mg ml À1 cycloheximide (CXM) for 8 h and western blot analysis was performed to analyze EphA 2 , P-AKT (serine 473), P-ERK and total AKT levels. (c) C4 cells were transduced with pSuper-Scrambled (shScram) and pSuper-shEphA 2 (shEphA 2 ) retroviruses and were selected with puromycin. Raf was activated and western blot analysis was performed to monitor P-AKT (serine 473), P-ERK and total AKT levels. (d) shScram and shEphA 2 C4 cells were treated or not with 1 mM R1881 for 32 h before being pulsed and stained for 5-bromodeoxyuridine incorporation.
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Upon activation of Raf in our cells, we observed a titratable increase in EphA 2 protein levels, consistent with previous results (Macrae et al., 2005) . Increased EphA 2 levels correlated with loss of AKT activity (Figure 4b ). Preventing EphA 2 upregulation with MEK and protein synthesis inhibitors, or shRNA directed against EphA 2 , was sufficient to prevent Rafinduced AKT inhibition and cellular arrest. From this work, we have developed a model whereby constitutive activation of the Raf-MAPK pathway switches on a negative feedback loop that inhibits the Ras-PI3K-AKT pathway through the upregulation of EphA 2 ( Figure 5 ). Our data identify the requirement of the inhibition of both Ras and AKT in eliciting the Raf-induced cellular arrest. Negative feedback inhibition of Ras, and consequently PI3K-AKT, has also been recently identified as an event in senescence, a process requiring cellular arrest (Courtois-Cox et al., 2006) . This study found Raf-induced negative feedback inhibition of Ras-PI3K-AKT through increased p120RasGAP and Sprouty 2 levels, as well as SOS phosphorylation by ERK (Courtois-Cox et al., 2006) . Although our model focuses on EphA 2 -mediated feedback inhibition of Ras, our data are consistent with all previous models where loss of Ras activity, and consequently PI3K-AKT activity, is required for cellular arrest and senescence, when the Raf-MAPK is hyperactivated in normal cells (Macrae et al., 2005; Courtois-Cox et al., 2006) .
Our model is consistent with recent papers that demonstrated that negative feedback inhibition of Ras is lost in cancers and required for cellular senescence (Macrae et al., 2005; Courtois-Cox et al., 2006) . Unlike these reports, our data link the events of EphA 2 -mediated negative feedback inhibition of Ras with Raf-induced loss of AKT activity and cellular arrest. Interestingly, the EphA 2 -mediated Ras inhibition is lost in both breast cancer and aggressive melanomas, due to loss of the EphA 2 ligand ephrin-1A (reviewed in Kinch and Carles-Kinch, 2003; Walker-Daniels et al., 2003) . In fact, adding back recombinant ephrin-1A ligand is a therapeutic treatment that can inhibit tumor growth and angiogenesis Cheng et al., 2002) .
Thus, both AKT inhibitors and Ras farnesyltransferase inhibitors may be useful therapeutics to arrest tumor cells (that is, breast cancer cells and aggressive melanomas) that have lost EphA 2 -mediated negative feedback inhibition of Ras.
Materials and methods
Plasmids pBabe-H-RasV12 (puro) and pcDNA myc-RAFCAAX plasmids were a generous gift from Dr Hartmut Land (University of Rochester) and Dr Julian Downward (London Institute, CRUK), respectively. shScram was cloned and described previously (Thrash et al., 2006) . shRNA against EphA 2 was cloned into pSuper-retro-puro (OligoEngine) as previously described (Thrash et al., 2006) with the following primers:
Cell culture, transfection and transduction RafAR conditional NIH-3T3 fibroblasts (clone C4) were a generous gift from Dr Hartmut Land (University of Rochester). C4 cells were maintained as previously described (Sewing et al., 1997; Westbrook et al., 2002) . NIH-3T3 fibroblasts were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. For stable transfection experiments, a total of 10 mg of pcDNA-NEO or pCMV-NEO-based vector (HA-CA-MEK1 and HA-CA-MEK2) or myc-Raf-CAAX was transfected in fibroblasts on a 10 cm dish. After 48 h, cells were selected in media containing 1 mg ml À1 geneticin (G418) for 2 weeks. G418-resistant cells were then harvested for western blot analysis.
For production of retroviruses, FNYX-GP cells were transfected with 37.5 mg of the appropriate retroviral backbone (pBabe or pSuper) and 37.5 mg of pCMV-VSVG (vesicular stomatitis virus coat envelope) using the calcium phosphate (BD Biosciences, San Jose, CA, USA) transfection method. Fortyeight hours later, the supernatant from the FNYX packaging cells was harvested and spun down at 15 000 r.p.m. for 90 min. The pelleted virus was resuspended in 3 ml of phenol red free Dulbecco's modified Eagle's medium supplemented with 10% charcoal-stripped newborn calf serum and 4 mg ml À1 polybrene, and then allowed to infect C4 fibroblasts overnight. Stable murine cells were then maintained in media containing 2.5 mg ml À1 puromycin and 1 mg ml À1 geneticin (G418).
Western blot analysis and Ras activity assays Western blot analysis was performed as previously described (Westbrook et al., 2002) . Ras activity was pulled down from cellular lysates utilizing recombinant GST-Raf-RNA binding domain protein as previously described (Cichowski et al., 2003) .
BrdU incorporation assay 5-Bromodeoxyuridine incorporation and staining on adherent C4 fibroblast was performed as previously described (Westbrook et al., 2002) .
Antibodies
The following antibodies and dilutions were used in this study: rabbit polyclonal anti-P-AKT (serine 473), anti-total AKT (Cell Signalling; 1:1000), mouse monoclonal actin (Santa Cruz, Figure 5 Model of Raf-induced EphA 2 -mediated negative feedback inhibition of Ras-PI3K-AKT during cellular arrest. Constitutive activation of Raf-MEK1 caused upregulation of EphA 2 , leading to negative feedback inhibition of Ras and, consequently, the PI3K-AKT pathway, allowing for cell cycle arrest.
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Raf-MEK1 regulates Ras-PI3K-AKT through EphA 2 CW Menges and DJ McCance Santa Cruz, CA, USA; 1:1000), mouse monoclonal antiPan-Ras (Calbiochem, San Diego, CA, USA; 1:250) and mouse monoclonal anti-Eck1/EphA 2 (Upstate, Billerica, MA, USA; 1:1000). Secondary antibodies used in this study were goat anti-rabbit-HRP, goat anti-mouse-HRP and donkey anti-goat-HRP (Santa Cruz; 1:2000) .
